Inhibitors of GdpP Phosphodiesterases in Bacteria

This approach not only enhances the immunostimulatory capabilities of probiotics but also provides a convenient, dietary-based method for delivering therapeutic agents, broadening the scope of preventive healthcare and offering substantial benefits to bot

Technology

The delivery of cyclic-di-AMP (c-di-AMP), a potent bacterial second messenger, has been a significant challenge, particularly with oral administration. This molecule is crucial for stimulating both innate and adaptive immune responses, making it an ideal candidate for probiotics as well as vaccine adjuvants and cancer immunotherapeutics. However, effective delivery mechanisms have been lacking, limiting its application potential. Researchers at the University of Delaware have identified small-molecule inhibitors of a widespread c-di-AMP phosphodiesterase (PDEs). These inhibitors increase intracellular c-di-AMP concentration in bacterial cells, facilitating its use in various applications. This discovery enables the development of commensals, such as probiotics, that can effectively trigger the host’s immune system. The inhibitors can be incorporated into probiotic formulations to enhance their immunostimulatory functions, offering a novel approach to immunoprophylaxis and therapeutic interventions. The integration of these inhibitors into probiotic formulations presents a unique opportunity to harness the natural benefits of probiotics for immunoprophylactic purposes. This approach not only enhances the immunostimulatory capabilities of probiotics but also provides a convenient, dietary-based method for delivering therapeutic agents, broadening the scope of preventive healthcare and offering substantial benefits to both healthcare providers and consumers.

Benefits

  • Enhanced Immune Response: Increases the magnitude, breadth, quality, and longevity of immune responses to vaccine antigens and anti-cancer drugs.
  • Targeted Immunomodulation: Allows for precise, time-controlled delivery of c-di-AMP, optimizing therapeutic outcomes for specific populations.
  • Dietary-Based Delivery:Utilizes probiotic formulations as a convenient and natural method for delivering immunotherapeutic agents, enhancing consumer accessibility and acceptance.
  • Reduced Dosage Requirements: Potentially decreases the number of doses needed for full immunity, improving patient compliance and reducing healthcare costs.

Applications

  • Vaccine adjuvant enhancement for improved immune response
  • Cancer immunotherapy with increased drug effectiveness
  • Immunoprophylactic probiotics for bacterial infection prevention